{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Allergies&page=2",
    "query": {
      "condition": "Multiple Allergies",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Allergies&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:43:22.920Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05432388",
      "title": "Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergy, Peanut"
      ],
      "interventions": [
        {
          "name": "remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 76,
      "start_date": "2022-10-12",
      "completion_date": "2025-03-11",
      "has_results": false,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432388"
    },
    {
      "nct_id": "NCT03915496",
      "title": "Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-04965842 200 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-06-18",
      "completion_date": "2021-11-16",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 9,
      "location_summary": "Encinitas, California • Los Angeles, California • Largo, Florida + 5 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03915496"
    },
    {
      "nct_id": "NCT03079687",
      "title": "Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-10-25",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Newport Beach, California • Roseville, California + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03079687"
    },
    {
      "nct_id": "NCT05891119",
      "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Caffeine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Rocatinlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-06-03",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 7,
      "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Dilworth",
          "state": "Minnesota"
        },
        {
          "city": "Camp Hill",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891119"
    },
    {
      "nct_id": "NCT00746330",
      "title": "Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mometasone furoate/formoterol fumarate (MFF)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg pMDI (F12M)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg DPI (F12D)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to F12D",
          "type": "DRUG"
        },
        {
          "name": "Placebo to F12M/MFF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 32,
      "start_date": "2008-08",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2011-06-07",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746330"
    },
    {
      "nct_id": "NCT03181009",
      "title": "Multi OIT to Test Immune Markers After Minimum Maintenance Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Food Flour Allergens",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Long, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-07-31",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Mountain View, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181009"
    },
    {
      "nct_id": "NCT02105012",
      "title": "Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "BD MDI 320 µg",
          "type": "DRUG"
        },
        {
          "name": "BD MDI 160 µg",
          "type": "DRUG"
        },
        {
          "name": "BD MDI 80 µg",
          "type": "DRUG"
        },
        {
          "name": "BD MDI 40 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 147,
      "start_date": "2014-04-01",
      "completion_date": "2015-09-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-06",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 41,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105012"
    },
    {
      "nct_id": "NCT00702325",
      "title": "Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide / formoterol fumarate (SYMBICORT)",
          "type": "DRUG"
        },
        {
          "name": "Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2008-06",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-11-09",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 57,
      "location_summary": "Pell City, Alabama • Bentonville, Arkansas • Hot Springs, Arkansas + 54 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Malvern",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702325"
    },
    {
      "nct_id": "NCT06072157",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "AK006-IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo-IV",
          "type": "DRUG"
        },
        {
          "name": "AK006-SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo-SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allakos Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 136,
      "start_date": "2023-08-28",
      "completion_date": "2025-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072157"
    },
    {
      "nct_id": "NCT04856865",
      "title": "ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Low dose ADP101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose ADP101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pooled Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alladapt Immunotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "4 Years to 55 Years"
      },
      "enrollment_count": 73,
      "start_date": "2021-04-20",
      "completion_date": "2022-12-13",
      "has_results": true,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-05-22T05:43:22.920Z",
      "location_count": 15,
      "location_summary": "Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856865"
    }
  ]
}